Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew P Deek

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
International Journal of Radiation Oncology, Biology, Physics|January 28, 2023
WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate CancerPhilip Sutera, Matthew P Deek, Kim Van der Eecken, et al.
European Urology|January 9, 2021
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory RevisitedMatthew P Deek, Kim Van der Eecken, Ryan Phillips, et al.
The Prostate|October 9, 2023
TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatmentTung Hoang, Philip Sutera, Triet Nguyen, et al.
Advances in Radiation Oncology|May 27, 2024
Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate CancerPhilip Sutera, Matthew P Deek, Rebecca A Deek, et al.
Clinical and Translational Radiation Oncology|January 24, 2023
Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancerNikhil Yegya-Raman, Timothy P Kegelman, Sang Ho Lee, et al.
BMC Cancer|June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
The Lancet. Oncology|February 5, 2026
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaborationChad Tang, Alex D Sherry, Hyunsoo Hwang, et al.
European Urology Oncology|April 3, 2024
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate CancerMatthew P Deek, Philip Sutera, Yuezhou Jing, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2024
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancerJarey H Wang, Matthew P Deek, Adrianna A Mendes, et al.
European Urology Oncology|June 11, 2024
Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate CancerPhilip Sutera, Yang Song, Amol C Shetty, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
International Journal of Radiation Oncology, Biology, Physics|January 28, 2023
WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate CancerPhilip Sutera, Matthew P Deek, Kim Van der Eecken, et al.
European Urology|January 9, 2021
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory RevisitedMatthew P Deek, Kim Van der Eecken, Ryan Phillips, et al.
The Prostate|October 9, 2023
TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatmentTung Hoang, Philip Sutera, Triet Nguyen, et al.
Advances in Radiation Oncology|May 27, 2024
Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate CancerPhilip Sutera, Matthew P Deek, Rebecca A Deek, et al.
Clinical and Translational Radiation Oncology|January 24, 2023
Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancerNikhil Yegya-Raman, Timothy P Kegelman, Sang Ho Lee, et al.
BMC Cancer|June 15, 2019
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA)Roche Kapoor, Matthew P Deek, Riley McIntyre, et al.
The Lancet. Oncology|February 5, 2026
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaborationChad Tang, Alex D Sherry, Hyunsoo Hwang, et al.
European Urology Oncology|April 3, 2024
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate CancerMatthew P Deek, Philip Sutera, Yuezhou Jing, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2024
Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancerJarey H Wang, Matthew P Deek, Adrianna A Mendes, et al.
European Urology Oncology|June 11, 2024
Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate CancerPhilip Sutera, Yang Song, Amol C Shetty, et al.
Pageof 8